Rethinking schizophrenia

Nature

Volumn 468, Issue 7321, 2010, Pages 187-193

  Insel, Thomas R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE;

BRAIN; DISEASE CONTROL; DISEASE TREATMENT; MENTAL HEALTH; NEUROLOGY; POPULATION DISTRIBUTION; POPULATION SIZE;

AUTISM; COGNITION; DIZYGOTIC TWINS; EFFECT SIZE; ENVIRONMENTAL FACTOR; FAMILY STRESS; HELP SEEKING BEHAVIOR; HISTORY; HOMELESSNESS; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MATERNAL NUTRITION; MONOZYGOTIC TWINS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURED INTERVIEW; UNEMPLOYMENT;

COGNITION DISORDERS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MODELS, NEUROLOGICAL; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 78149428430     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature09552     Document Type: Review

References (100)

1. Hegarty, J.D., Baldessarini, R. J., Tohen, M., Waternaux, C.&Oepen, G.One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am. J. Psychiatry 151, 1409-1416 (1994).
2. Robinson, D. G., Woerner, M. G., McMeniman, M., Mendelowitz, A. & Bilder, R. M. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 161, 473-479 (2004).
3. Harrison, G. et al. Recovery from psychotic illness: a 15-and 25-year international follow-up study. Br. J. Psychiatry 178, 506-517 (2001).
4. Marwaha, S. et al. Rates and correlates of employment in people with schizophreniaintheUK, Franceand Germany. Br.J.Psychiatry191, 30-37(2007).
5. Folsom, D. P. et al. Prevalence and risk factors for homelessness and utilization of mental health services among 10, 340 patients with serious mental illness in a large public mental health system. Am. J. Psychiatry 162, 370-376 (2005).
6. Kraepelin, E.Dementia Praecox and Paraphrenia (Chicago MedicalBook Co., 1919).
7. Bleuler, E. Dementia Praecox or the Group of Schizophrenias (International Universities Press, 1950).
8. Arieti, S. Interpretation of Schizophrenia (Basic Books, 1974).
9. Carlsson, A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1, 179-186 (1988).
10. Lieberman, J. A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223 (2005).
11. Coyle, J. T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 26, 363-382 (2006).
12. Kety, S. S. The significance of genetic factors in the etiology of schizophrenia: results from the national study of adoptees in Denmark. J. Psychiatr. Res. 21, 423-429 (1987).
13. McGuffin, P. & Gottesman, I. I. Risk factors for schizophrenia. N. Engl. J. Med. 341, 370-372 (1999).
14. Cardno, A.G.et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch. Gen. Psychiatry 56, 162-168 (1999).
15. Stefansson, H. et al. Common variants conferring risk of schizophrenia. Nature 460, 744-747 (2009).
16. The International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748-752 (2009).
17. Ettinger, U. et al. Prefrontal and striatal volumes in monozygotic twins concordant and discordant for schizophrenia. Schizophr. Bull. doi: 10.1093/schbul/sbq060 (10 June 2010).
18. Hahn, C. G. et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nature Med. 12, 824-828 (2006).
19. Rujescu, D. et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum. Mol. Genet. 18, 988-996 (2009).
20. Huffaker, S. J. et al. A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia. Nature Med. 15, 509-518 (2009).
21. Straub, R. E. et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 71, 337-348 (2002).
22. McClellan, J. & King, M. C. Genetic heterogeneity in human disease. Cell 141, 210-217 (2010).
23. Need, A.C.et al.A genome-wide investigationofSNPs and CNVsin schizophrenia. PLoS Genet. 5 e1000373 (2009).
24. Bassett, A. S., Scherer, S. W. & Brzustowicz, L. M. Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. Am. J. Psychiatry 167, 899-914 (2010).
25. Brandon, N. J. et al. Understanding the role of DISC1 in psychiatric disease and during normal development. J. Neurosci. 29, 12768-12775 (2009).
26. Feinberg, I.Schizophrenia: caused byafaultinprogrammed synaptic elimination during adolescence? J. Psychiatr. Res. 17, 319-334 (1982).
27. Weinberger, D. R.Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44, 660-669 (1987).
28. Murray, R. M., Jones, P. & O'Callaghan, E. Fetal brain development and later schizophrenia. Ciba Found. Symp. 156, 155-170 (1991).
29. Lewis, D. A. & Levitt, P. Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 25, 409-432 (2002).
30. Jaaro-Peled, H. et al. Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci. 32, 485-495 (2009).
31. Fair, D. A. et al. The maturing architecture of the brain's default network. Proc. Natl Acad. Sci. USA 105, 4028-4032 (2008).
32. Paus, T., Keshavan, M. & Giedd, J. N. Why do many psychiatric disorders emerge during adolescence? Nature Rev. Neurosci. 9, 947-957 (2008).
33. Huttenlocher, P. R. Synapse elimination and plasticity in developing human cerebral cortex. Am. J. Ment. Defic. 88, 488-496 (1984).
34. Yakovlev, P. & Lecours, A. R. in Regional Development of the Brain in Early Life (ed. Minkowski, A.) (Blackwell Scientific, 1967).
35. Rakic, P., Bourgeois, J. P., Eckenhoff, M. F., Zecevic, N. & Goldman-Rakic, P. S. Concurrent overproduction ofsynapses indiverse regions ofthe primate cerebral cortex. Science 232, 232-235 (1986).
36. A receptor a1 and a2 subunit expression in primate prefrontal cortex. Biol. Psychiatry 65, 1015-1023 (2009).
37. Lewis, D. A. & Gonzalez-Burgos, G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 33, 141-165 (2008).
38. Rosenberg, D. R. & Lewis, D. A. Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: a tyrosine hydroxylase immunohistochemical analysis. J. Comp. Neurol. 358, 383-400 (1995).
39. Lambe, E. K., Krimer, L. S. & Goldman-Rakic, P. S. Differential postnatal development of catecholamine and serotonin inputs to identified neurons in prefrontal cortex of rhesus monkey. J. Neurosci. 20, 8780-8787 (2000).
40. Sørensen, H. J. et al. Early developmental milestones and risk of schizophrenia: a 45-yearfollow-up of the Copenhagen PerinatalCohort. Schizophr. Res. 118, 41-47 (2010).
41. Woodberry, K. A., Giuliano, A. J. & Seidman, L. J. Premorbid IQ in schizophrenia: a meta-analytic review. Am. J. Psychiatry 165, 579-587 (2008).
42. Reichenberg, A. et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am. J. Psychiatry 167, 160-169 (2010).
43. Walsh, T. et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320, 539-543 (2008).
44. Li, W. et al. Specific developmental disruption of disrupted-in- schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc. Natl Acad. Sci. USA 104, 18280-18285 (2007).
45. Niwa, M. et al. Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron 65, 480-489 (2010).
46. Tan, W. et al. Molecular cloning of a brain-specific, developmentally regulated neuregulin 1 (NRG1) isoform and identification of a functional promoter variant associated with schizophrenia. J. Biol. Chem. 282, 24343-24351 (2007).
47. Colantuoni, C. et al. Age-related changes in the expression of schizophrenia susceptibility genes in the human prefrontal cortex. Brain Struct. Funct. 213, 255-271 (2008).
48. Nakata, K. et al. DISC1 splice variants are upregulated in schizophrenia and associated with risk polymorphisms. Proc. Natl Acad. Sci. USA 106, 15873-15878 (2009).
49. Guilmatre, A. et al. Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Arch. Gen. Psychiatry 66, 947-956 (2009).
50. Susser, E.S.&Lin, S.P.Schizophrenia afterprenatal exposuretotheDutchHunger Winter of 1944-1945. Arch. Gen. Psychiatry 49, 983-988 (1992).
51. St Clair, D. et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. J. Am. Med. Assoc. 294, 557-562 (2005).
52. Brown, A. S. & Derkits, E. J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 167, 261-280 (2010).
53. Cannon, M., Jones, P. B. & Murray, R. M. Obstetric complications and schizophrenia: historical and meta-analytic review. Am. J. Psychiatry 159, 1080-1092 (2002).
54. Ellman, L. M. et al. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr. Res. 121, 46-54 (2010).
55. Nicodemus, K. K. et al. Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Mol. Psychiatry 13, 873-877 (2008).
56. Feinberg, A. P. & Irizarry, R. A. Evolution in health and medicine Sackler colloquium: Stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and disease. Proc. Natl Acad. Sci. USA 107 (suppl. 1), 1757-1764 (2010).
57. Gregory, S. G. et al. Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC Med. 7, 62 (2009).
58. Thompson, B.L.&Levitt, P.Nowyou see it, now you don't- closinginonallostasis and developmental basis of psychiatric disorders. Neuron 65, 437-439 (2010).
59. Gogtay, N. et al. Comparison of progressive cortical gray matter loss in childhood-onset schizophrenia with that in childhood-onset atypical psychoses. Arch. Gen. Psychiatry 61, 17-22 (2004).
60. Rapoport, J. L. et al. Progressive cortical change during adolescence in childhood-on setschizophrenia. Alongitudinal magneticresonance imagingstudy. Arch. Gen. Psychiatry 56, 649-654 (1999).
61. Karayiorgou, M., Simon, T. J. & Gogos, J. A. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nature Rev. Neurosci. 11, 402-416 (2010).
62. Bassett, A.S.et al.Theschizophrenia phenotypein22q11 deletion syndrome.Am. J. Psychiatry 160, 1580-1586 (2003).
63. Chow, E. W., Watson, M., Young, D. A. & Bassett, A. S. Neurocognitive profile in 22q11 deletion syndrome and schizophrenia. Schizophr. Res. 87, 270-278 (2006).
64. Mukai, J. et al. Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. Nature Neurosci. 11, 1302-1310 (2008).
65. Stark, K. L. et al. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nature Genet. 40, 751-760 (2008).
66. McGorry, P. D., Yung, A. R., Bechdolf, A. & Amminger, P. Back to the future: predicting and reshaping the course of psychotic disorder. Arch. Gen. Psychiatry 65, 25-27 (2008).
67. Nestler, E. J. & Hyman, S. E. Animal models of neuropsychiatric disorders. 13, 1161-1169 (2010).
68. Cannon, T. D. et al. Childhood cognitive functioning in schizophrenia patients and their unaffected siblings: a prospective cohort study. Schizophr. Bull. 26, 379-393 (2000).
69. Cornblatt, B., Obuchowski, M., Roberts, S., Pollack, S. & Erlenmeyer-Kimling, L. Cognitive and behavioral precursors of schizophrenia. Dev. Psychopathol. 11, 487-508 (1999).
70. Erlenmeyer-Kimling, L. et al. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project. Am. J. Psychiatry 157, 1416-1422 (2000).
71. Henry, L.P.et al. The EPPIC follow-up studyof first-episode psychosis: longer-term clinical andfunctional outcome7years after index admission. J.Clin.Psychiatry 71 716-728 (2010).
72. Yung, A.R.et al. Validationof"prodromal" criteriatodetect individualsatultra high risk of psychosis: 2 year follow-up. Schizophr. Res. 105, 10-17 (2008).
73. Woods, S. W. et al. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr. Bull. 35, 894-908 (2009).
74. Cannon, T. D. et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 65, 28-37 (2008).
75. Smieskova, R. et al. Neuroimaging predictors of transition to psychosis-a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 34, 1207-1222 (2010).
76. Cohen, J. D., Barch, D. M., Carter, C. & Servan-Schreiber, D. Context-processing deficits in schizophrenia: converging evidence from three theoretically motivated cognitive tasks. J. Abnorm. Psychol. 108, 120-133 (1999).
77. Seidman, L. J. et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch. Gen. Psychiatry 67, 578-588 (2010).
78. Riecher-Rössler, A.et al.Efficacy ofusing cognitive statusinpredicting psychosis: a 7-year follow-up. Biol. Psychiatry 66 1023-1030 (2009).
79. Kremen, W. S. et al. Cognitive decline inschizophrenia from childhoodto midlife: a 33-year longitudinal birth cohort study. Schizophr. Res. 118, 1-5 (2010).
80. Carter, C. S., Barch, D. M., Gur, R., Pinkham, A. & Ochsner, K. CNTRICS final task selection: social cognitive and affective neuroscience-based measures. Schizophr. Bull. 35, 153-162 (2009).
81. Woods, S. W. et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol. Psychiatry 54, 453-464 (2003).
82. Cornblatt, B. A. et al. Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. J. Clin. Psychiatry 68, 546-557 (2007).
83. Berger, G. et al. Neuroprotection in emerging psychotic disorders. Early Interv. Psychiatry 1, 114-127 (2007).
84. Morrison, A. P. et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry 185, 291-297 (2004).
85. Amminger, G. P. et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 67, 146-154 (2010).
86. Keefe, R. S. et al. Report from the Working Group Conference on multisite trial design for cognitive remediation in schizophrenia. Schizophr. Bull. doi:10.1093/ schbul/sbq010 (1 March 2010).
87. Hyman, S. E. & Fenton, W. S. Medicine. What are the right targets for psychopharmacology? Science 299, 350-351 (2003).
88. Kirkpatrick, B., Buchanan, R. W., Ross, D.E.&Carpenter, W.T. Jr. A separate disease within the syndrome ofschizophrenia. Arch. Gen. Psychiatry 58, 165-171 (2001).
89. Buchanan, R.W.et al.Asummaryofthe FDA-NIMH-MATRICS workshoponclinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 31, 5-19 (2005).
90. Kirkpatrick, B., Fenton, W.S., Carpenter, W.T.Jr&Marder, S.R.The NIMH-MATRICS consensusst at ement on negativesymptoms. Schizophr. Bull. 32, 214-219(2006).
91. Keefe, R. S. et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 164, 1061-1071 (2007).
92. Swartz, M. S. et al. Effects of antipsychotic medications on psychosocial functioninginpatients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry 164, 428-436 (2007).
93. Editor. Where next with psychiatric illness? Nature 336, 95-96 (1988).
94. Alaräisänen, A. et al. Suicide rate in schizophrenia in the Northern Finland 1966 Birth Cohort. Soc. Psychiatry Psychiatr. Epidemiol. 44, 1107-1110 (2009).
95. Kelly, D. L. et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr. Bull. doi:10.1093/schbul/sbp152 (17 December 2009).
96. McEvoy, J. P. et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80, 19-32 (2005).
97. Colton, C. W. & Manderscheid, R. W. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev. Chronic Dis. 3, A42 (2006).
98. Harvey, P. D., Reichenberg, A., Bowie, C. R., Patterson, T. L. & Heaton, R. K. The course of neuropsychological performance and functional capacity in older patients with schizophrenia: influences of previous history of long-term institutional stay. Biol. Psychiatry 67, 933-939 (2010).
99. Bell, M. D., Zito, W., Greig, T. & Wexler, B. E. Neurocognitive enhancement therapy with vocationalservices: work outcomesattwo-year follow-up. Schizophr.Res. 105, 18-29 (2008).
100. Takahashi, H. et al. Impact of changing the Japanese term for "schizophrenia" for reasonsofstereotypical beliefsofschizophrenia inJapanese youth. Schizophr. Res. 112, 149-152 (2009).